Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Martin Prázný"'
Autor:
Martin Prázný, Lyudmila Suplotova, Janusz Gumprecht, Zdravko Kamenov, Tibor Fülöp, Alexey Medvedchikov, Doron Rosenzweig, Milos Aleksandric
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-17 (2022)
Abstract Background Guidelines from 2016 onwards recommend early use of SGLT2i or GLP-1 RA for patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), to reduce CV events and mortality. Many eligible patients are not treated accordingly
Externí odkaz:
https://doaj.org/article/df7c4cf2f24543638cbd7bffdc452ab4
The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-11 (2021)
Abstract Patients with Covid-19 place new challenges on the management of type 2 diabetes, including the questions of whether glucose-lowering therapy should be adjusted during infection and how to manage a return to normal care after resolution of C
Externí odkaz:
https://doaj.org/article/0dafb8b6594847eebbfd1bdddfd35c76
Autor:
Guntram Schernthaner, Avraham Karasik, Agnė Abraitienė, Alexander S. Ametov, Zsolt Gaàl, Janusz Gumprecht, Andrej Janež, Susanne Kaser, Katarina Lalić, Boris N. Mankovsky, Evgeny Moshkovich, Marju Past, Martin Prázný, Gabriela Radulian, Lea Smirčić Duvnjak, Ivan Tkáč, Kārlis Trušinskis
Publikováno v:
Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-9 (2019)
Abstract EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of e
Externí odkaz:
https://doaj.org/article/8d398bf5b3cb4286a35496a80a088901
Autor:
Guntram Schernthaner, Heinz Drexel, Evgeny Moshkovich, Birute Zilaitiene, Emil Martinka, Leszek Czupryniak, Tamás Várkonyi, Andrej Janež, Kristine Ducena, Katarina Lalić, Tsvetalina Tankova, Martin Prázný, Lea Smirčić Duvnjak, Olga Sukhareva, Harald Sourij
Publikováno v:
BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-13 (2019)
Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively manda
Externí odkaz:
https://doaj.org/article/0272f69452424381adfcfdd3590cbea1
Autor:
Guntram Schernthaner, Roger Lehmann, Martin Prázný, Leszek Czupryniak, Kristine Ducena, Peter Fasching, Andrej Janež, Avraham Karasik, Peter Kempler, Emil Martinka, Marina V. Shestakova, Lea Smirčić Duvnjak, Tsvetalina Tankova
Publikováno v:
Cardiovascular Diabetology, Vol 16, Iss 1, Pp 1-12 (2017)
Abstract Aims These recommendations aim to improve care for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk in Central and Eastern Europe. Cardiovascular disease (CVD) and/or chronic kidney disease (CKD) are major interdependent
Externí odkaz:
https://doaj.org/article/a98d192fce5b47699289f36bd5e7e85e
Autor:
Lucie Radovnická, Aneta Hásková, Quoc Dat Do, Eva Horová, Vendula Navrátilová, Ondřej Mikeš, David Cihlář, Christopher G. Parkin, George Grunberger, Martin Prázný, Jan Šoupal
Publikováno v:
Diabetes Technology & Therapeutics. 24:859-867
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fffe7f52c909feb8317be50432fa5eb4
https://doi.org/10.1089/dia.2022.0152
https://doi.org/10.1089/dia.2022.0152
Publikováno v:
Diabetes Therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f74991271b24ef8aacd25900be6a2fc8
https://doi.org/10.1007/s13300-023-01422-4
https://doi.org/10.1007/s13300-023-01422-4
Autor:
Martin Prázný
Publikováno v:
Vnitřní lékařství. 68:96-103
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8a5c9413f103a297642d79b23c2b950
https://doi.org/10.36290/vnl.2022.019
https://doi.org/10.36290/vnl.2022.019
Autor:
Petr Ošťádal, Miloš Táborský, Aleš Linhart, Michal Vrablík, Richard Češka, Renata Cífková, Eva Králíková, Věra Adámková, Martin Prázný, Zorjan Jojko
Publikováno v:
Cor et Vasa. 64:7-28
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9c68589bd9831b113eaf9400c239edc
https://doi.org/10.33678/cor.2021.140
https://doi.org/10.33678/cor.2021.140
Autor:
Martin Haluzik, Markéta Kubíčková, Jan Škrha, Filip Málek, Miloš Táborský, Jiří Veselý, Martin Prázný, Aleš Linhart
Publikováno v:
Vnitřní lékařství. 67:404-410
Diabetes mellitus je významným rizikovým faktorem rozvoje srdecniho selhani a přitomnost diabetu zaroveň zhorsuje prognozu nemocných se srdecnim selhanim. Jednou z významných novinek v lecbě srdecniho selhani jsou glifloziny, ktere blokadou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd835a8c58d78e7911fad57fcfb8d79b
https://doi.org/10.36290/vnl.2021.108
https://doi.org/10.36290/vnl.2021.108